Table 1.
Observed information in the EHR | Estimated distribution for all N=8,345 patients | ||||||
---|---|---|---|---|---|---|---|
|
|||||||
Full sample | Invited to participate | Survey respondents | |||||
|
|||||||
N | % | n* | % | n | % | % | |
Total | 8,345 | 2,109 | 1,153 | ||||
Female | 5,823 | 70 | 1,398 | 66 | 790 | 69 | 72 |
Age, years | |||||||
<= 35 | 1,570 | 19 | 430 | 20 | 175 | 15 | 22 |
(35, 40] | 760 | 9 | 190 | 9 | 98 | 9 | 8 |
(40, 45] | 833 | 10 | 213 | 10 | 100 | 9 | 12 |
(45, 50] | 1,065 | 13 | 275 | 13 | 142 | 12 | 11 |
(50, 55] | 1,261 | 15 | 305 | 14 | 187 | 16 | 14 |
> 55 | 2,856 | 34 | 696 | 33 | 451 | 39 | 33 |
Diagnosis | |||||||
Major depressive episode - single | 1,817 | 22 | 416 | 20 | 215 | 19 | 26 |
Major depressive episode - recurrent | 2,534 | 30 | 641 | 30 | 343 | 30 | 28 |
Dysthymia | 672 | 8 | 204 | 10 | 114 | 10 | 10 |
Depression NOS | 3,322 | 40 | 848 | 40 | 481 | 41 | 36 |
Anxiety disorder | 2,880 | 35 | 714 | 34 | 353 | 31 | 34 |
Sleep disorder | 698 | 8 | 131 | 6 | 81 | 7 | 8 |
Smoker in the prior 9 months | 1,491 | 18 | 322 | 15 | 134 | 12 | 20 |
Treatment type | |||||||
Psychotherapy | 1,485 | 18 | 566 | 27 | 317 | 28 | 17 |
Mirtazipine/Paroxetine | 363 | 4 | 202 | 10 | 116 | 10 | 4 |
Buproprion/Fluoxetine | 2,837 | 34 | 688 | 33 | 367 | 32 | 33 |
Other | 3,660 | 44 | 653 | 31 | 353 | 30 | 46 |
Weight information in the EHR | |||||||
Complete BL and FU | 5,630 | 67 | 337 | 16 | 197 | 17 | 70 |
BL missing w/visit | 623 | 8 | 518 | 25 | 273 | 24 | 7 |
BL missing w/o visit | 1,271 | 15 | 741 | 35 | 402 | 35 | 14 |
BL complete & FU missing w visit | 77 | 1 | 76 | 4 | 41 | 4 | 1 |
BL complete & FU missing w/o visit | 744 | 9 | 437 | 21 | 240 | 21 | 8 |